180 Life Sciences Corp. Pursuing Novel Solutions to Inflammatory Illnesses as Merger Nears Completion
180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF when the deal closes later this year Analysts forecast the anti-inflammatory therapeutics market will be worth $191.42 billion by 2027, growing at a CAGR of 3 percent 180 Life Sciences is completing phase 2b/3 clinical trials tackling fibrosis and inflammation-causing TNF substance aberrations The sudden and surprise impact of the…











